Butler MO, Sotov V, Nelles M, et a. Adoptive T cell therapy with TBI-1301 results in gene-engineered T cell persistence and anti-tumor responses in patients with NY-ESO-1 expressing solid tumors. Presented at: European Society for Medical Oncology (ESMO) 2019 Annual Meeting; September 27-October 01, 2019; Barcelona, Spain. Abstract 1183PD.
Carmagnani Pestana R, Groisberg R, Roszik J, Subbiah V. Precision oncology in sarcomas: divide and conquer. JCO Precis Oncol. 2019;2019.
ClinicalTrials.gov. A Study of DCC-2618 vs sunitinib in advanced GIST patients after treatment with imatinib (INTRIGUE). https://clinicaltrials.gov/ct2/show/NCT03673501. Accessed October 15, 2019.
ClinicalTrials.gov. Phase II study of regorafenib as maintenance therapy. https://clinicaltrials.gov/ct2/show/NCT03793361. Accessed October 15, 2019.
ClinicalTrials.gov. Pulmonary Resectable metastases of osteosarcoma with apatinib and chemotherapy (PROACH). https://clinicaltrials.gov/ct2/show/NCT03742193. Accessed October 15, 2019.
ClinicalTrials.gov. Spearhead 1 Study in subjects with advanced synovial sarcoma or myxoid/round cell liposarcoma. https://clinicaltrials.gov/ct2/show/NCT04044768. Accessed October 15, 2019.
D'Angelo SP, Mahoney MR, Van Tine BA, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018;19:416-426.
D'Angelo SP, Melchiori L, Merchant MS, et al. Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 c259T cells in synovial sarcoma. Cancer Discov. 2018;8:944-957.
Davis LE, Bolejack V, Ryan CW, et al. Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma. J Clin Oncol. 2019;37:1424-1431.
Doebele RC, Dziadziuszko R, Drilon A, et al. Genomic landscape of entrectinib resistance from ctDNA analysis in STARTRK2. Presented at: European Society for Medical Oncology (ESMO) 2019 Annual Meeting; September 27-October 01, 2019; Barcelona, Spain. Abstract LBA28.
Doebele R, Paz-Ares L, Farago AF, et al. Entrectinib in NTRK-fusion positive (NTRK-FP) non-small cell lung cancer (NSCLC): integrated analysis of patients enrolled in three trials (STARTRK-1, STARTRK-1 and ALKA-372-001). Cancer Res. 2019;79:CT131.
Drilon A, Cho BC, Kim DW, et al. Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1/TRK fusion-positive solid tumors (TRIDENT-1 study). Presented at: European Society for Medical Oncology (ESMO) 2019 Annual Meeting; September 27-October 01, 2019; Barcelona, Spain. Abstract 444PD.
Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378:731-739.
Drilon A, Ou SI, Cho BC, et al. Repotrectinib (TPX-0005) Is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent-front mutations. Cancer Discov. 2018;8:1227-1236.
Duffaud F, Blay JY, Italiano A, et al. Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REGO) in patients (pts) with locally advanced (LA) or metastatic relapsed chrondosarcoma (CS), on behalf of the French Sarcoma Group (FSG) and UNICANCER. Presented at: European Society for Medical Oncology (ESMO) 2019 Annual Meeting; September 27-October 01, 2019; Barcelona, Spain. Abstract LBA88.
Duffaud F, Mir O, Boudou-Rouquette P, et al. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2019;20:120-133.
George S, Heinrich M, Chi P, et al. Initial results of phase 1 study of DCC-2618, a broad-spectrum KIT and PDGFR⍺ inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens. Presented at: European Society for Medical Oncology (ESMO) 2019 Annual Meeting; September 27-October 01, 2019; Barcelona, Spain. Abstract 1603O.
Gounder MM, Mahoney MR, Van Tine BA, et al. Sorafenib for advanced and refractory desmoid tumors. N Engl J Med. 2018;379:2417-2428.
Groisberg R, Hong DS, Behrang A, et al. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer. 2017;5:100.
Groisberg R, Hong DS, Holla V, et al. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget. 2017;8:39254-39267.
Hattori H, Ishihara M, Kitano S, et al. A novel affinity-enhanced NY-ESO-1-targeting TCR-redirected T cell transfer exhibited early-onset cytokine release syndrome and subsequent tumor responses in synovial sarcoma patients. Presented at: European Society for Medical Oncology (ESMO) 2019 Annual Meeting; September 27-October 01, 2019; Barcelona, Spain. Abstract 1182PD.
Hyman DM, van Tilburg CM, Albert CM, et al. Durability of response with larotectinib in adult and paediatric patients with TRK fusion cancer. Presented at ESMO Congress 2019; September 27-October 1, 2019; Barcelona, Spain. Abstract 445PD.
Iura K, Maekawa A, Kohashi K, et al. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1. Hum Pathol. 2017;61:130-139.
Jones RL, Ravi V, Brohl A, et al. An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcomas (TAPPAS). Presented at: European Society for Medical Oncology (ESMO) 2019 Annual Meeting; September 27-October 01, 2019; Barcelona, Spain. Abstract 1667O.
Martin Broto J, Alvarez RM, Fabre P, et al. Trabectedin with concurrent low-dose of radiation therapy for metastatic soft tissue sarcomas: A phase II trial of Spanish, French and Italian sarcoma groups. Presented at: European Society for Medical Oncology (ESMO) 2019 Annual Meeting; September 27-October 01, 2019; Barcelona, Spain. Abstract 1674PD.
Martin Broto J, Hindi N, Grignani G, et al. IMMUNOSARC: a collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I/II trial of sunitinib plus nivolumab in advanced soft tissue and bone sarcomas: results of the phase II- soft-tissue sarcoma cohort. Presented at: European Society for Medical Oncology (ESMO) 2019 Annual Meeting; September 27-October 01, 2019; Barcelona, Spain. Abstract 1669O.
Nathenson M, Hemming ML, Malik K, et al. Molecular characterization and management of secondary resistance to serial TRK inhibitors. J Clin Oncol. 2019;37(suppl):e22547.
Penel N, Blay JY, Wallet J, et al. Prior exposure to pazopanib (PAZ) did not reduce efficacy of regorafenib (REG) in non-adipocyte soft tissue sarcoma patients (pts). Presented at: European Society for Medical Oncology (ESMO) 2019 Annual Meeting; September 27-October 01, 2019; Barcelona, Spain. Abstract 1695P.
Siden EG, Park JJ, Zoratti MJ, et al. Reporting of master protocols towards a standardized approach: a systematic review. Contemp Clin Trials Comm. 2019;15:100406.
Stacchiotti S, Schöffski P, Jones RL, et al. Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients with epithelioid sarcoma (ES) (NCT02601950). Presented at: 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO®); May 31-June 4, 2019. Chicago, IL. Abstract 11003.
Subbiah V, Anderson PM, Kairemo K, et al. Alpha particle radium 223 dichloride in high-risk osteosarcoma: a phase I dose escalation trial. Clin Cancer Res. 2019;25:3802-3810.
Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label phase 2 trial. Lancet Oncol. 2017;18:1493-1501.
Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015;5:25-34.
Van Tine BA, Butler MO, Johnson ML, et al. ADP-A2M4 (MAGE-A4) in patients with synovial sarcoma. Presented at ESMO Congress 2019; September 27-October 1, 2019; Barcelona, Spain. Abstract 1670O.
Wilky BA, Trucco MM, Subhawong TK, et al. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. Lancet Oncol. 2019;20:837-848.
Wilson TR, Sokol ES, et al. Trabucco SE, et al. Genomic characteristics and predicted ancestry of NTRK1/2/3 and ROS1 fusion-positive tumours from >165,000 pan-solid tumours. Presented at: European Society for Medical Oncology (ESMO) 2019 Annual Meeting; September 27-October 01, 2019; Barcelona, Spain. Abstract 443PD.
Yonemori K, Shimizu T, Hirakawa A, et al. A phase II biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, disease with a high unmet need. Presented at: European Society for Medical Oncology (ESMO) 2019 Annual Meeting; September 27-October 01, 2019; Barcelona, Spain. Abstract 1732TiP.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Vivek Subbiah, MD

Associate Professor
Department of Investigational Cancer Therapeutics, Division of Cancer Medicine
Executive Director, Medical Oncology Research
MD Anderson Cancer Network® Center
Medical Director, Clinical Center for Targeted Therapy
Associate Professor, Division of Pediatrics
University of Texas MD Anderson Cancer
Houston, Texas, United States

Disclosures

Disclosure: Vivek Subbiah, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Helsinn Therapeutics, Inc
Received grants for clinical research from: Abbvie; Agensys; Alfa-sigma; Amgen; Bayer AG; Berghealth; Boston Biomedical; Blueprint medicines; Celgene; D3; Exelixis; Fujifilm; GlaxoSmithKline; Helsi; Incyte; Inhbrx; Idera Pharma; Loxo oncology; Multivir; Nanocarrier; Northwest Biotherapeutics; Novartis, Vegenics, Pfizer; Pharmamar; Takeda and Roche/ Genentech

Jean-Yves Blay, MD

Directeur Général-General director
Centre Léon Bérard
Lyon, France

Disclosures

Disclosure: Jean-Yves Blay, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer AG; Bristol-Meyers Squibb Company; Deciphera; Novartis; PharmaMar; Roche
Received grants for clinical research from: Bayer AG; Deciphera; GlaxoSmithKline; Novartis; PharmaMar; Roche

Roman Groisberg, MD

Assistant Professor –Medical Oncology
Department of Melanoma and Sarcoma
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey

Disclosures

Disclosure: Roman Groisberg, MD, has disclosed no relevant financial relationships

Editor

Melinda Tanzola, PhD

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Melinda Tanzola, PhD, has disclosed no relevant financial relationships.

CME Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME / ABIM MOC

Clinical Updates in Evolving Treatment Strategies for Sarcoma

Authors:

Vivek Subbiah, MD; Jean-Yves Blay, MD; Roman Groisberg, MD

CME / ABIM MOC Released: 10/31/2019
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 10/31/2020, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for oncologists.

The goal of this activity is to improve clinicians' knowledge about emerging approaches for the treatment of sarcoma.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Biological and clinical rationale for emerging and new treatment strategies for sarcoma
- Clinical evidence for emerging and new treatment strategies for sarcoma
- Potential role of emerging multi-targeted and oncogenic driver therapies in the treatment paradigm for sarcoma

Disclosures

Faculty

Vivek Subbiah, MD

Associate Professor
Department of Investigational Cancer Therapeutics, Division of Cancer Medicine
Executive Director, Medical Oncology Research
MD Anderson Cancer Network® Center
Medical Director, Clinical Center for Targeted Therapy
Associate Professor, Division of Pediatrics
University of Texas MD Anderson Cancer
Houston, Texas, United States

Disclosures

Disclosure: Vivek Subbiah, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Helsinn Therapeutics, Inc
Received grants for clinical research from: Abbvie; Agensys; Alfa-sigma; Amgen; Bayer AG; Berghealth; Boston Biomedical; Blueprint medicines; Celgene; D3; Exelixis; Fujifilm; GlaxoSmithKline; Helsi; Incyte; Inhbrx; Idera Pharma; Loxo oncology; Multivir; Nanocarrier; Northwest Biotherapeutics; Novartis, Vegenics, Pfizer; Pharmamar; Takeda and Roche/ Genentech

Jean-Yves Blay, MD

Directeur Général-General director
Centre Léon Bérard
Lyon, France

Disclosures

Disclosure: Jean-Yves Blay, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer AG; Bristol-Meyers Squibb Company; Deciphera; Novartis; PharmaMar; Roche
Received grants for clinical research from: Bayer AG; Deciphera; GlaxoSmithKline; Novartis; PharmaMar; Roche

Roman Groisberg, MD

Assistant Professor –Medical Oncology
Department of Melanoma and Sarcoma
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey

Disclosures

Disclosure: Roman Groisberg, MD, has disclosed no relevant financial relationships

Editor

Melinda Tanzola, PhD

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Melinda Tanzola, PhD, has disclosed no relevant financial relationships.

CME Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC

Clinical Updates in Evolving Treatment Strategies for Sarcoma

Authors: Vivek Subbiah, MD; Jean-Yves Blay, MD; Roman Groisberg, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 10/31/2019

Valid for credit through: 10/31/2020, 11:59 PM EST

processing....

AE = adverse event
ALK = anaplastic lymphoma kinase
ASPS = alveolar soft part sarcoma
CR = complete response
ctDNA = circulating tumor DNA
ESMO = European Society for Medical Oncology
EZH2 = enhancer of zeste homolog 2
FDG = fluorodeoxyglucose
GIST - gastrointestinal stromal tumors
MAPK = mitogen-activated protein kinase
mDOR = median duration of response
mOS = median overall survival
mPFS = median progression-free survival
NaF = sodium fluoride
NGS = next-generation sequencing
NSCLC = non-small cell lung cancer
ORR = overall response rate
OS = overall survival
PAZ = pazopanib
PD = progressive disease
PD-1 = programmed death-1
PDGFR = platelet-derived growth factor receptor
PET = positron emission tomography
PFS = progression-free survival
PI3K = phosphoinositide 3-kinase
PR = partial response
REG = regorafenib
SD = stable disease
siRNA = small interfering RNA
STS = soft tissue sarcoma
TKI = tyrosine kinase inhibitor
TRAE = treatment-related adverse event
TRK = tropomyosin receptor kinase
VEGF = vascular endothelial growth factor
VEGFR2 = vascular endothelial growth factor receptor 2

« Return to: Clinical Updates in Evolving Treatment Strategies for Sarcoma

CME / ABIM MOC Information Download Slides

Print
Like Tweet

References

Faculty and Disclosures

Faculty

Vivek Subbiah, MD

Jean-Yves Blay, MD

Roman Groisberg, MD

Editor

Melinda Tanzola, PhD

CME Reviewer

Robert Morris, PharmD

CME / ABIM MOC

Clinical Updates in Evolving Treatment Strategies for Sarcoma

Target Audience and Goal Statement

Disclosures

Faculty

Vivek Subbiah, MD

Jean-Yves Blay, MD

Roman Groisberg, MD

Editor

Melinda Tanzola, PhD

CME Reviewer

Robert Morris, PharmD

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Clinical Updates in Evolving Treatment Strategies for Sarcoma